为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

西地尼布, 血管内皮生长因子受体抑制剂

规格或纯度: ≥98%
有货

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
C125911-10mg
10mg 现货 Stock Image
C125911-50mg
50mg 现货 Stock Image

基本描述

别名 西地尼布
英文别名 AZD2171|NSC755606|NSC-755606|MFCD09954115|Recentin|Cediranib - AZD2171|D08881|N-acetyl-N-formyl-5-methoxykynuramine|XXJWYDDUDKYVKI-UHFFFAOYSA-N|A24280|AZD 2171|HY-10205|ZD-2171|SCHEMBL157630|4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin
规格或纯度 ≥98%
英文名称 Cediranib
生化机理 Cediranib is VEGFR2 inhibitor. Cediranib inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50s of 0.4 and 0.5 nM, respectively.
储存温度 -20°C储存
运输条件 超低温冰袋运输
产品介绍

Cediranib (AZD2171)是一种高效的VEGFR(KDR)抑制剂,IC50为<1 nM,同时也抑制Flt1/4,IC50为5 nM/≤3 nM,此外对c-Kit和PDGFRβ也具有相似的抑制活性,对VEGFR的选择性比PDGFR-α, CSF-1R和Flt3分别高36倍, 110倍 和1000倍以上。Phase 3。

Cediranib (AZD2171) is a highly potent VEGFR(KDR) inhibitor with IC50 of <1 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM, similar activity against c-Kit and PDGFRβ, 36-, 110-fold and >1000-fold selective more for VEGFR than PDGFR-α, CSF-1R and Flt3, Phase 3.

产品属性

ALogP 4.9

名称和标识符

IUPAC Name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
INCHI InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
InChi Key XXJWYDDUDKYVKI-UHFFFAOYSA-N
Canonical SMILES CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
Isomeric SMILES CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
PubChem CID 9933475
分子量 450.52

化学和物理性质

溶解性 DMSO 90 mg/mL Water <1 mg/mL Ethanol <1 mg/mL

安全和危险性(GHS)

象形图
ghs06

Toxic

ghs08

Health Hazard

ghs09

Environmental Hazard

ghs07

Harmful

信号词 Danger
危险声明 H315: Causes skin irritation
H301: Toxic if swallowed
H312: Harmful in contact with skin
H410: Very toxic to aquatic life with long lasting effects
H372: Causes damage to organs through prolonged or repeated exposure
H361: Suspected of damaging fertility or the unborn child
预防措施声明 P273,P280,P302+P352,P321,P405,P501,P264,P260,P270,P362+P364,P391,P330,P203,P301+P316,P318,P317,P332+P317,P319

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO et al..  (2005)  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer..  Cancer Res,  65  (10):  (4389-400).  [PMID:15899831]